research JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
Search
for
Sort by
Research
180-210 / 1000+ results 
research Advances in the management of alopecia areata
New treatments for severe hair loss often fail, but some patients see hair regrowth with specific therapies, and treatment should be tailored to the individual's situation.
research Monotherapy for Alopecia Areata: A Systematic Review and Network Meta-Analysis
Intralesional corticosteroids work best for mild alopecia areata, and DPCP works best for moderate to severe cases.
research Alopecia areata in a renal transplant recipient on cyclosporin
A kidney transplant patient on cyclosporin experienced unexpected severe hair loss, which improved with treatment adjustments.
research Alopecia Areata Treatment Patterns and Satisfaction: Results of a Real-World Cross-Sectional Survey in Europe
Current treatments for severe alopecia areata are unsatisfactory, highlighting the need for better options.
research 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
research Alopecia areata
Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
research Estimation of Claudin 3 in the Sreum of Alopecia Areata Patients and Its Association with Disease Severity
Higher Claudin 3 levels in the blood are linked to more severe alopecia areata.
research Correlation of vitamin D and vitamin D receptor expression in patients with alopecia areata: a clinical paradigm
People with alopecia areata often have lower vitamin D levels, which are linked to more severe and longer-lasting hair loss, but vitamin D receptor levels in the skin don't show the same pattern and don't predict treatment success.
research Cutaneous Reactions in Patients with Chronic Hepatitis C Treated with Peginterferon and Ribavirin
Some patients treated with peginterferon and ribavirin for chronic hepatitis C had mild to moderate skin reactions, but treatment did not need to be stopped.
research Gene Expression of Osteopontin in Alopecia Areata? A Case-Controlled Study
People with alopecia areata have higher levels of osteopontin, which might be important in the disease's development, but this doesn't relate to how severe the disease is.
research Topical immunotherapy in alopecia areata
Topical immunotherapy, especially with DPCP, is effective for treating severe alopecia areata.
research A novel therapeutic paradigm for patients with extensive alopecia areata
New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
research Serum level of interleukin-15 in active alopecia areata patients and its relation to age, sex, and disease severity
Higher interleukin-15 levels are linked to more severe alopecia areata, but not to age or gender.
research Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib—A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata
A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
research Intramuscular Corticosteroid Therapy in the Treatment of Alopecia Areata: A Time-to-Event Analysis
Intramuscular corticosteroids are effective and safe for severe alopecia areata, with most patients regrowing hair, but nearly half may relapse.
research Increase in IL-15 levels in patients with alopecia areata
Higher IL-15 levels are linked to more severe hair loss in alopecia areata.
research ASSESSMENT OF SERUM LEVELS OF ANTIGLIADIN ANTIBODIES (IgG and IgA) IN PATIENTS WITH ALOPECIA AREATA AND THEIR RELATION TO SEVERITY OF THE DISEASE
Higher antigliadin antibodies are linked to more severe alopecia areata, suggesting screening for celiac disease in these patients.
research Serum 25-Hydroxy Vitamin D Level in Patients with Alopecia Areata and Its Relationship with Severity of the Disease
Lower vitamin D levels are linked to more severe alopecia areata.
research Risk factors for the development of and outcomes after diagnosis of autoimmune alopecia areata in patients with inflammatory bowel diseases
IBD patients treated with TNF antagonists may develop autoimmune alopecia areata, with severe cases less likely to improve.
research La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
research Increased serum interleukin-17A levels correlate with disease severity and poor prognostic factors in patients with alopecia areata
Higher IL-17A levels indicate more severe alopecia areata.
research Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries
AA patients with comorbid conditions face more severe hair loss and need specific treatments.
research Efficacy of Dupilumab in Patients with Atopic Dermatitis and Alopecia Areata: A Case Series
Dupilumab may help hair regrowth in some patients with severe atopic dermatitis, but results vary.
research Evaluation of serum zinc level in patients with Alopecia Areata
Lower zinc levels are linked to more severe hair loss in alopecia areata.
research A clinical study on alopecia areata
Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.
research Large doses of glucocorticoid in the treatment of alopecia areata
Large doses of glucocorticoids are not suitable for general use in treating severe alopecia areata due to inconsistent results and risks.
research Alopecia areata: a long‐term follow‐up study of 104 patients
Older age at onset of alopecia areata leads to less severe and shorter episodes, with most patients experiencing significant hair regrowth.
research Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.